AbbVie将投资380万加元投资到两座新的北美芝加哥工厂, 用于神经科学和肥胖药物, 2029年启动300个新工作。 AbbVie to invest $380M in two new North Chicago plants for neuroscience and obesity drugs, launching in 2029 with 300 new jobs.

AbbVie将投资3.8亿美元,在芝加哥北部建造两座新的制药厂,利用先进技术,包括人工智能,为神经科学和肥胖治疗生产活性成分。 AbbVie will invest $380 million to build two new pharmaceutical manufacturing plants in North Chicago, using advanced technologies including artificial intelligence to produce active ingredients for neuroscience and obesity treatments. 2026年春季开始施工,预计2029年开工。 Construction begins in spring 2026, with operations expected by 2029. 该项目包括雇用300名新雇员,是未来十年美国1 000亿美元投资承诺的一部分,与特朗普政府的一项自愿协议挂钩,涉及关税豁免和降低药品价格。 The project includes hiring 300 new employees and is part of a broader $100 billion U.S. investment commitment over the next decade, tied to a voluntary agreement with the Trump administration involving tariff exemptions and drug price reductions. 这一扩张支持国内制造业增长,同时支持贸易政策的转变。 The expansion supports domestic manufacturing growth amid shifting trade policies.